




RealRate

PHARMACEUTICAL 2018

Vanda Pharmaceuticals Inc
Rank 139 of 332



The relative strengths and weaknesses of Vanda Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Vanda Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 298%, being 46% points above the market average of 252%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	169,857	Assets	205,425
Cost of Goods Sold	0	Liabilities	74,038
Intangible Assets	26,069	Expenses	182,122
Liabilities, Current	70,363	Revenues	166,555
Liabilities, Non-Current	3,675	Stockholders Equity	131,387
Other Assets	4,193	Net Income	-15,567
Other Compr. Net Income	-92	Comprehensive Net Income	-15,613
Other Expenses	19,734	BaseVar	314,116
Other Liabilities	0	ECR before LimitedLiability	194%
Other Net Income	0	Economic Capital Ratio	298%
Other Revenues	166,555		
Property and Equipment	5,306		
Research and Development	38,547		
Selling, General and Administrative Expense	123,841		